

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Jun 2026

Comparison the therapeutic effect of Clonidine, Yohimbine and Nalterexone on removing the ovarian cyst in poly-cystic ovary syndrome patients referred to Valie-Asre Clinical Center, Imam Khomeini Hospital, Tehran

Protocol summary

Summary

Women with polycystic ovary syndrome have significantly higher sympathetic nerve activity than their control groups and the increased sympathetic outflow is related to hormonal and metabolic features. Polycystic ovary is characterized by increased luteinizing hormone pulse frequency and amplitude and it is well known that one of the major neurotransmitters that control luteinizing hormone secretion is noradrenaline. The central Beta-endorphin system has a regulatory role in reproduction and autonomic functions. Beta-endorphin is inhibitory modulator of the Gonadotropin releasing hormone pulse generator and pituitary luteinizing hormone release. Thus polycystic ovary syndrome may partly result from insufficient central Beta-endorphin inhibition of Gonadotropin releasing hormone. The aim of evaluation effect of three drugs: Nalterxone, Clonidine and Yohimbine is decreasing overactivity of sympathetic nervous system. Clonidine and yohimbine are used for sympathetic agonist and antagonist and Nalterxone is used for opioid system inhibition, because endogenous opioids have modulating role on catecholamine secretion. Eighty eight women with polycystic ovary syndrome, aging 20-40 years were divided into four groups: three drug groups and one control group. Drugs are: Nalterxone capsule 0.5 mg. daily after dinner, Clonidine tablet 0.2 mg. twice 0.1 mg. after breakfast and dinner and Yohimbine tablet 0.5 mg. after dinner for two mounts. The patients had no systemic medical disease, history of medication and their body mass index was less than 28. The main outcomes measurement in this study are serum levels of estradiol, FSH, LH, insulin and also adrenaline, noradrenaline, Beta-endorphine and cortisol.

General information

Acronym

polycystic ovary syndrome PCOS

IRCT registration information

IRCT registration number: **IRCT201204027883N4**

Registration date: **2012-05-23, 1391/03/03**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-05-23, 1391/03/03

Registrant information

Name

Farideh Zangeneh

Name of organization / entity

Vali-e-Asr, Reproductive Health Research Center,
Tehran University of Medical Sciences, Tehran, Iran

Country

Iran (Islamic Republic of)

Phone

+98 21 6658 1616

Email address

fzafari@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice-chancellor for research- Tehran University Medical Sciences

Expected recruitment start date

2012-04-20, 1391/02/01

Expected recruitment end date

2013-04-21, 1392/02/01

Actual recruitment start date

empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Comparison the therapeutic effect of Clonidine, Yohimbine and Nalterexone on removing the ovarian cyst in poly-cystic ovary syndrome patients referred to Valie-Asre Clinical Center, Imam Khomeini Hospital, Tehran

Public title
Effect of Clonidine, Yohimbine and Nalterexone on polycystic ovary syndrome patients

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria: female, age20-40 and they are suffering of Polycystic ovary syndrome exclusion criteria:Body Mass Index:28, without basis disease and must not use drug.

Age
From **20 years** old to **40 years** old

Gender
Female

Phase
N/A

Groups that have been masked
No information

Sample size
Target sample size: **88**

Randomization (investigator's opinion)
Not randomized

Randomization description

Blinding (investigator's opinion)
Single blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Vice-chancellor for research of Tehran University Medical Sciences
Street address
Central building of Tehran University of Medical Sciences
City
Tehran
Postal code

Approval date
2012-01-27, 1390/11/07
Ethics committee reference number
90-03-39-15359

Health conditions studied

1

Description of health condition studied
Polycystic ovary syndrome
ICD-10 code
E28.2
ICD-10 code description
Sclerocystic ovary syndrome Stein-Leventhal syndrome

Primary outcomes

1

Description
Estradiol,LH/FSH and Insuline
Timepoint
before intervention and after two mounts of it
Method of measurement
Utilization of diagnosis kite of Elisa

Secondary outcomes

1

Description
Adrenaline, Noradrenaline,Beta endorphine and Cortisol
Timepoint
Before intervention and two mounts of it
Method of measurement
Utilization of diagnosis Elisa kite

Intervention groups

1

Description
Nalterxone capsule 50 mg. after dinner
Category
Treatment - Drugs

2

Description
Clonidine tablet 0.2 mg. twice 0.1 mg. after breakfast and dinner.
Category
Treatment - Drugs

3

Description
Yohimbine tablet 0.5 mg. after dinner.
Category
Treatment - Drugs

4

Description

Control group: Placebo, capsule without drug.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Valie Asr Reproductive Health Research Center,
Tehran University of Medical Sciences.

Full name of responsible person

Dr. Farideh Zafari Zangeneh, Pharmacist, Ph.D of
Physiology

Street address

No.2 Valie Asr Hospital, Imam khomeini hospital
complex, Tehran

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice- chanellor for research, Tehran University
Medical Sciences

Full name of responsible person

Dr. Akbar Fotouhee, Research Accessory of university

Street address

Research managment, BLV. Keshavarz, , Ghods
street, central building of Tehran University of
Medical Sciences

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice- chanellor for research, Tehran University Medical
Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Research managment

Full name of responsible person

Dr. Younessian

Position

Research managment/Epidemiology

Other areas of specialty/work

Street address

BLV. Keshavarz, Ghods street, Central building of
Tehran University Medical Sciences

City

Tehran

Postal code

Phone

+98 21 8163 3513

Fax

Email

research@tums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Vali e Asr Reproductive Health Research Center,
Tehran University Medical Sciences, Tehran University

Full name of responsible person

Farideh Zafari Zangeneh

Position

PhD.of Physiology

Other areas of specialty/work

Street address

Valie Asr Reproductive Health Research Center, Valie
Asr Hospital No. 2 , Imam Khomeini Hospital Complex,
Tehran University of Medical Sciences.

City

Tehran

Postal code

Phone

+98 21 6658 1616

Fax

Email

zangeneh14@gmail.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Valie Asr Reproductive Health Research Center,
Tehran University of Medical Sciences.

Full name of responsible person

Farideh Zafari Zangeneh

Position

Ph.D, Assistant Professor

Other areas of specialty/work

Street address

No.2 Valie Asr Hospital, Imam khomeini hospital

complex, Tehran, Iran ,

City

Tehran

Postal code

Phone

+98 21 6658 1616

Fax

Email

zangeneh14@gmail.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty